891494-64-7Relevant articles and documents
A convergent preparation of the CHK1 inhibitor MK-8776 (SCH 900776)
Labroli, Marc A.,Dwyer, Michael P.,Poker, Cory,Keertikar, Kerry M.,Rossman, Randall,Guzi, Timothy J.
, p. 2601 - 2603 (2016/06/01)
This Letter describes the development of a convergent, efficient route to the CHK1 inhibitor MK-8776. This synthetic approach relies upon the cyclization of a bispyrazole adduct 10 with a optically pure β-keto nitrile 9 to construct the pyrazolo[1,5-a]pyrimidine scaffold in a single step.
COMPOSITIONS AND METHODS FOR TREATING CANCER
-
, (2013/03/28)
The instant invention provides a method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer and ovarian cancer, by administering a combination of a WEE1 inhibitor and a CHK1 inhibitor, wherein the WEE1 inhibitor is MK-1775 or a pharmaceutically acceptable salt thereof, or MK-3652 or a pharmaceutically acceptable salt thereof, and the CHK1 inhibitor is MK-8776 or a pharmaceutically acceptable salt thereof, or SCH900444 or a pharmaceutically acceptable salt thereof.